The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Open accessAbstract
It is now well established that the immune system can recognize developing cancers and that therapeutic manipulation of immunity can induce tumor regression. The capacity to manifest remarkably durable responses in some patients has been ascribed in part to T cells that can (a) kill tumor cells directly, (b) orchestrate diverse antitumor immune responses, (c) manifest long-lasting memory, and (d) display remarkable specificity for tumor-derived proteins. This specificity stems from fundamental differences between cancer cells and their normal counterparts in that the former develop protein-altering mutations and undergo epigenetic and genetic alterations, resulting in aberrant protein expression. These events can result in formation of tumor antigens. The identification of mutated and aberrantly expressed self-tumor antigens has historically been time consuming and laborious. While mutant antigens are usually expressed in a tumor-specific manner, aberrantly expressed antigens are often shared between cancers and, therefore, in the past, have been the major focus of therapeutic cancer vaccines. However, advances in next-generation sequencing and epitope prediction now permit the rapid identification of mutant tumor neoantigens. This review focuses on a discussion of mutant tumor neoantigens and their use in personalizing cancer immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Structure of the human class I histocompatibility antigen, HLA-A2
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987) · Nature · doi:10.1038/329506a0 · Cited by 3,472
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationThe Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 3×
“Most of the reported studies indicate that natural immune responses to tumor neoantigens are selectively directed to epitopes within a group predicted to have the strongest MHCI binding affinities (44, 77, 78).”
BackgroundResultSelf-citationThe IPD and IMGT/HLA database: allele variant databases
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1161 · Cited by 1,740
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Pathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,547
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,422
Self-citationLong term culture of tumour-specific cytotoxic T cells
GILLIS, S., & SMITH, K. A. (1977) · Nature · doi:10.1038/268154a0 · Cited by 1,386
Parker, K. C., Bednarek, M. A., & Coligan, J. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.1.163 · Cited by 1,370
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Self-citationA dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Self-citationMutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Binding of immunogenic peptides to Ia histocompatibility molecules
Babbitt, B. P., Allen, P. M., Matsueda, G., Haber, E., & Unanue, E. R. (1985) · Nature · doi:10.1038/317359a0 · Cited by 1,195
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Human neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
The immune epitope database (IEDB) 3.0
Vita, R., Overton, J. A., Greenbaum, J. A., Ponomarenko, J., Clark, J. D., Cantrell, J. R., Wheeler, D. K., Gabbard, J. L., Hix, D., Sette, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku938 · Cited by 1,052
Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
Larsen, M. V., Lundegaard, C., Lamberth, K., Buus, S., Lund, O., & Nielsen, M. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-424 · Cited by 982
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., & Nielsen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn202 · Cited by 808
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · cited 1×
“Concomitantly, Schumacher used a combination of exome sequencing and high-throughput MHC tetramer screening to show that checkpoint blockade immunotherapy facilitated expansion of preexisting T cells specific for tumor neoantigens in a human melanoma patient (45).”
MethodDoes the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
NetMHCpan, a method for MHC class I binding prediction beyond humans
Hoof, I., Peters, B., Sidney, J., Pedersen, L. E., Sette, A., Lund, O., Buus, S., & Nielsen, M. (2009) · Immunogenetics · doi:10.1007/s00251-008-0341-z · Cited by 753
Kaer, L. V., Ashton-Rickardt, P. G., Ploegh, H. L., & Tonegawa, S. (1992) · Cell · doi:10.1016/s0092-8674(05)80068-6 · Cited by 724
Nielsen, M., Lundegaard, C., Blicher, T., Lamberth, K., Harndahl, M., Justesen, S., Røder, G., Peters, B., Sette, A., Lund, O., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000796 · Cited by 719
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.
Ej, F. (1953) · PubMed · Cited by 690
Direct selection of human genomic loci by microarray hybridization
Albert, T. J., Molla, M. N., Muzny, D. M., Nazareth, L., Wheeler, D., Song, X., Richmond, T. A., Middle, C. M., Rodesch, M. J., Packard, C. J., et al. (2007) · Nature Methods · doi:10.1038/nmeth1111 · Cited by 681
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Next-Generation Sequencing Platforms
Mardis, E. R. (2013) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-062012-092628 · Cited by 667
Self-citationCentral tolerance: learning self-control in the thymus
Hogquist, K. A., Baldwin, T. A., & Jameson, S. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1707 · Cited by 659
Nielsen, M., Lundegaard, C., & Lund, O. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-238 · Cited by 594
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Peters, B., & Sette, A. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-132 · Cited by 512
Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
Trinchieri, G. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075008 · Cited by 511
Nielsen, M., & Lund, O. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-296 · Cited by 510
Nielsen, M., Lundegaard, C., Lund, O., & Keşmir, C. (2005) · Immunogenetics · doi:10.1007/s00251-005-0781-7 · Cited by 491
GENERATION OF CYTOTOXIC T LYMPHOCYTES IN VITRO
Cerottini, J.-C., Engers, H. D., MacDonald, H. R., & Brunner, K. T. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.140.3.703 · Cited by 478
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Duan, F., Duitama, J., Al Seesi, S., Ayres, C. M., Corcelli, S. A., Pawashe, A. P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 378
Prediction of MHC class I binding peptides using profile motifs
Reche, P. A., Glutting, J.-P., & Reinherz, E. L. (2002) · Human Immunology · doi:10.1016/s0198-8859(02)00432-9 · Cited by 375
Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line
Gross, L. (1943) · Cancer Research · Cited by 360
Ohminami, H., Yasukawa, M., & Fujita, S. (2000) · Blood · doi:10.1182/blood.v95.1.286 · Cited by 347
Identifying MHC Class I Epitopes by Predicting the TAP Transport Efficiency of Epitope Precursors
Peters, B., Bulik, S., Tampe, R., van Endert, P. M., & Holzhütter, H.-G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1741 · Cited by 339
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
Rajasagi, M., Shukla, S. A., Fritsch, E. F., Keskin, D. B., DeLuca, D., Carmona, E., Zhang, W., Sougnez, C., Cibulskis, K., Sidney, J., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567933 · Cited by 309
De Plaen, E., Lurquin, C., Van Pel, A., Mariamé, B., Szikora, J. P., Wölfel, T., Sibille, C., Chomez, P., & Boon, T. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.7.2274 · Cited by 308
Hammer, J., Bono, E., Gallazzi, F., Belunis, C., Nagy, Z., & Sinigaglia, F. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2353 · Cited by 290
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., T.Siegel, C., & Schreiber, H. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 241
TCR contact residue hydrophobicity is a hallmark of immunogenic CD8 + T cell epitopes
Chowell, D., Krishna, S., Becker, P. D., Cocita, C., Shu, J., Tan, X., Greenberg, P. D., Klavinskis, L. S., Blattman, J. N., & Anderson, K. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500973112 · Cited by 239
Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research
Lin, H. H., Ray, S., Tongchusak, S., Reinherz, E. L., & Brusic, V. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-8 · Cited by 239
Knuth, A., Danowski, B., Oettgen, H. F., & Old, L. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3511 · Cited by 236
Heemskerk, B., Kvistborg, P., & Schumacher, T. N. M. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.333 · Cited by 227
Database of T cell-defined human tumor antigens: the 2013 update.
Vigneron, N., Stroobant, V., den Eynde, B. J. V., & van der Bruggen, P. (2013) · Europe PMC (PubMed Central) · Cited by 226
Zhou, J., Dudley, M. E., Rosenberg, S. A., & Robbins, P. F. (2005) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00007 · Cited by 225
Kim, Y., Sidney, J., Pinilla, C., Sette, A., & Peters, B. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-394 · Cited by 219
MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia
Cobbold, M., De La Peña, H., Norris, A., Polefrone, J. M., Qian, J., English, A. M., Cummings, K. L., Penny, S., Turner, J. E., Cottine, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006061 · Cited by 204
Gnjatic, S., Atanackovic, D., Jäger, E., Matsuo, M., Selvakumar, A., Altorki, N. K., Maki, R. G., Dupont, B., Ritter, G., Chen, Y.-T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133324100 · Cited by 203
HLA-Binding Properties of Tumor Neoepitopes in Humans
Fritsch, E. F., Rajasagi, M., Ott, P. A., Brusic, V., Hacohen, N., & Wu, C. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0227 · Cited by 190
Hodges, E., Rooks, M., Xuan, Z., Bhattacharjee, A., Benjamin Gordon, D., Brizuela, L., Richard McCombie, W., & Hannon, G. J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.68 · Cited by 177
Neural network-based prediction of candidate T-cell epitopes
Honeyman, M. C., Brusic, V., Stone, N. L., & Harrison, L. C. (1998) · Nature Biotechnology · doi:10.1038/nbt1098-966 · Cited by 176
Wick, D. A., Webb, J. R., Nielsen, J. S., Martin, S. D., Kroeger, D. R., Milne, K., Castellarin, M. L., Twumasi‐Boateng, K., Watson, P. H., Holt, R. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2147 · Cited by 167
Dubey, P., Hendrickson, R. C., Meredith, S. C., Siegel, C., Shabanowitz, J., Skipper, J., Engelhard, V. H., Hunt, D. F., & Schreiber, H. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.695 · Cited by 161
Zhang, L., Udaka, K., Mamitsuka, H., & Zhu, S. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr060 · Cited by 160
Kawashima, I., Tsai, V., Southwood, S., Takesako, K., Sette, A., & Celis, E. (1999) · PubMed · Cited by 127
Modeling the adaptive immune system: predictions and simulations
Lundegaard, C., Lund, O., Keşmir, C., Brunak, S., & Nielsen, M. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm471 · Cited by 125
Stone, J. D., Harris, D. T., & Kranz, D. M. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.003 · Cited by 122
Prediction of epitopes using neural network based methods
Lundegaard, C., Lund, O., & Nielsen, M. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.10.011 · Cited by 114
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
van Buuren, M. M., Calis, J. J. A., & Schumacher, T. N. (2014) · OncoImmunology · doi:10.4161/onci.28836 · Cited by 96
HLA ligandome tumor antigen discovery for personalized vaccine approach
Rammensee, H., & Singh‐Jasuja, H. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836911 · Cited by 92
The validity of predicted T-cell epitopes
Lundegaard, C., Nielsen, M., & Lund, O. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.10.001 · Cited by 64
Targeted Exon Sequencing by In‐Solution Hybrid Selection
Blumenstiel, B. S., Cibulskis, K., Fisher, S., DeFelice, M. T., Barry, A. J., Fennell, T. J., Abreu, J., Minie, B., Costello, M., Young, G., et al. (2010) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1804s66 · Cited by 62
Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity
Doyle, H. A., Zhou, J., Wolff, M. J., Harvey, B. P., Roman, R. M., Gee, R. J., Koski, R. A., & Mamula, M. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604847200 · Cited by 62
cDNA Hybrid Capture Improves Transcriptome Analysis on Low-Input and Archived Samples
Cabanski, C. R., Magrini, V. J., Griffith, M., Griffith, O. L., McGrath, S. D., Zhang, J., Walker, J., Ly, A., Demeter, R., Fulton, R. S., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.03.004 · Cited by 53
Self-citation
Cited by
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Metadata
- Authors
- Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-08-10
- Volume
- 125
- Issue
- 9
- Pages
- 3413-3421
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1607316259
- Cited by
- 613
- References
- 102
- FWCI
- 22.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.